Impact of OATP transporters on pharmacokinetics

Membrane transporters are now recognized as important determinants of the transmembrane passage of drugs. Organic anion transporting polypeptides (OATP) form a family of influx transporters expressed in various tissues important for pharmacokinetics. Of the 11 human OATP transporters, OATP1B1, OATP1B3 and OATP2B1 are expressed on the sinusoidal membrane of hepatocytes and can facilitate the liver uptake of their substrate drugs. OATP1A2 is expressed on the luminal membrane of small intestinal enterocytes and at the blood‐brain barrier, potentially mediating drug transport at these sites. Several clinically used drugs have been identified as substrates of OATP transporters (e.g. many statins are substrates of OATP1B1). Some drugs may inhibit OATP transporters (e.g. cyclosporine) causing pharmacokinetic drug–drug interactions. Moreover, genetic variability in genes encoding OATP transporters can result in marked inter‐individual differences in pharmacokinetics. For example, a single nucleotide polymorphism (c.521T > C, p.Val174Ala) in the SLCO1B1 gene encoding OATP1B1 decreases the ability of OATP1B1 to transport active simvastatin acid from portal circulation into the liver, resulting in markedly increased plasma concentrations of simvastatin acid and an enhanced risk of simvastatin‐induced myopathy. SLCO1B1 polymorphism also affects the pharmacokinetics of many other, but not all (fluvastatin), statins and that of the antidiabetic drug repaglinide, the antihistamine fexofenadine and the endothelin A receptor antagonist atrasentan. This review compiles the current knowledge about the expression and function of human OATP transporters, their substrate and inhibitor specificities, as well as pharmacogenetics.

[1]  Shiyao Xu,et al.  Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein , 2007, Journal of Pharmacology and Experimental Therapeutics.

[2]  P. Meier,et al.  Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. , 1995, Gastroenterology.

[3]  Yuichi Sugiyama,et al.  Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics , 2003, Clinical pharmacology and therapeutics.

[4]  P. Neuvonen,et al.  Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2007, Clinical pharmacology and therapeutics.

[5]  P. Neuvonen,et al.  Rifampin decreases the plasma concentrations and effects of repaglinide , 2000, Clinical pharmacology and therapeutics.

[6]  P. Neuvonen,et al.  Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[7]  D. Keppler,et al.  Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. , 2008, Expert opinion on drug metabolism & toxicology.

[8]  R. Kim,et al.  Effect of Grapefruit Juice Volume on the Reduction of Fexofenadine Bioavailability: Possible Role of Organic Anion Transporting Polypeptides , 2005, Clinical pharmacology and therapeutics.

[9]  U. Hofmann,et al.  Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). , 2005, British journal of clinical pharmacology.

[10]  Martin F. Fromm,et al.  The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3 , 2007, Drug Metabolism and Disposition.

[11]  V. Schuster,et al.  Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). , 1996, The Journal of clinical investigation.

[12]  M. Niemi,et al.  Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin , 2006, Pharmacogenetics and genomics.

[13]  R. Kim,et al.  Transporters and drug therapy: Implications for drug disposition and disease , 2005, Clinical pharmacology and therapeutics.

[14]  T. Abe,et al.  LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. , 2001, Gastroenterology.

[15]  J. Xu,et al.  DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1 , 2005, Drug Metabolism and Disposition.

[16]  N. Ballatori,et al.  Human organic anion transporter 1B1 and 1B3 function as bidirectional carriers and do not mediate GSH-bile acid cotransport. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[17]  C. Gui,et al.  Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. , 2008, European journal of pharmacology.

[18]  T. Abe,et al.  Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Neuvonen,et al.  Pharmacokinetics and Pharmacodynamics of Pravastatin in Pediatric and Adolescent Cardiac Transplant Recipients on a Regimen of Triple Immunosuppression , 2004, Clinical pharmacology and therapeutics.

[20]  P. Meier,et al.  Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain , 1998, FEBS letters.

[21]  M. Niemi,et al.  The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism‐based Inhibition of CYP2C8 In Vivo , 2008, Clinical pharmacology and therapeutics.

[22]  J. Nezu,et al.  Involvement of Human Organic Anion Transporting Polypeptide OATP-B (SLC21A9) in pH-Dependent Transport across Intestinal Apical Membrane , 2003, Journal of Pharmacology and Experimental Therapeutics.

[23]  R. Kim,et al.  Human Organic Anion Transporting Polypeptide-C (SLC21A6) Is a Major Determinant of Rifampin-Mediated Pregnane X Receptor Activation , 2003, Journal of Pharmacology and Experimental Therapeutics.

[24]  P. Dawson,et al.  Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine , 2002, Clinical pharmacology and therapeutics.

[25]  R. Kim,et al.  Naringin is a Major and Selective Clinical Inhibitor of Organic Anion‐Transporting Polypeptide 1A2 (OATP1A2) in Grapefruit Juice , 2007, Clinical pharmacology and therapeutics.

[26]  R. Kim,et al.  Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. , 2006, Gastroenterology.

[27]  Paul D. Martin,et al.  The effect of gemfibrozil on the pharmacokinetics of rosuvastatin , 2004, Clinical pharmacology and therapeutics.

[28]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[29]  D. Keppler,et al.  Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). , 2004, Pharmacogenetics.

[30]  Sien‐Sing Yang,et al.  Genetic factors related to unconjugated hyperbilirubinemia amongst adults , 2005, Pharmacogenetics and genomics.

[31]  A. Kalliokoski Effects of SLCO1B1 polymorphism on the pharmacokinetics of the oral antidiabetic drugs repaglinide, nateglinide, rosiglitazone, and pioglitazone , 2008 .

[32]  D. Keppler,et al.  Hepatic Uptake of Bilirubin and Its Conjugates by the Human Organic Anion Transporter SLC21A6* , 2001, The Journal of Biological Chemistry.

[33]  D. Rosskopf,et al.  Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1 , 2008, Pharmacogenetics and genomics.

[34]  M. Leider Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[35]  E. Shimizu,et al.  Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. , 2007, Therapeutic drug monitoring.

[36]  D. Keppler,et al.  A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[37]  T. Abe,et al.  Molecular characterization of human and rat organic anion transporter OATP-D. , 2003, American journal of physiology. Renal physiology.

[38]  K. Maeda,et al.  Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans , 2004, Journal of Pharmacology and Experimental Therapeutics.

[39]  D. Keppler,et al.  Molecular characterization and inhibition of amanitin uptake into human hepatocytes. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[40]  P. Neuvonen,et al.  Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance , 2006, Clinical pharmacology and therapeutics.

[41]  M. Niemi,et al.  Influence of Drug Transporter Polymorphisms on Pravastatin Pharmacokinetics in Humans , 2007, Pharmaceutical Research.

[42]  P. Neuvonen,et al.  Cyclosporine markedly raises the plasma concentrations of repaglinide , 2005, Clinical pharmacology and therapeutics.

[43]  V. Sasseville,et al.  A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2) , 1999, The Journal of Biological Chemistry.

[44]  K. Mizuguchi,et al.  Organic Anion Transporting Polypeptides of the OATP/SLCO Superfamily: Identification of New Members in Nonmammalian Species, Comparative Modeling and a Potential Transport Mode , 2006, The Journal of Membrane Biology.

[45]  K. Maeda,et al.  INVOLVEMENT OF TRANSPORTERS IN THE HEPATIC UPTAKE AND BILIARY EXCRETION OF VALSARTAN, A SELECTIVE ANTAGONIST OF THE ANGIOTENSIN II AT1-RECEPTOR, IN HUMANS , 2006, Drug Metabolism and Disposition.

[46]  Mikko Niemi,et al.  SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid , 2006, Pharmacogenetics and genomics.

[47]  P. Neuvonen,et al.  No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone. , 2008, British journal of clinical pharmacology.

[48]  P. Neuvonen,et al.  Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide , 2008, Pharmacogenetics and genomics.

[49]  P. Neuvonen,et al.  Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites , 2005, Clinical pharmacology and therapeutics.

[50]  T. Cuddy,et al.  An open‐label study on the pharmacokinetics (PK) of pitavastatin (NK‐104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers , 2004 .

[51]  P. Neuvonen,et al.  Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population , 2006, European Journal of Clinical Pharmacology.

[52]  I. Binet,et al.  Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. , 2000, Kidney international.

[53]  H. Yawo,et al.  Identification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1* , 1999, The Journal of Biological Chemistry.

[54]  Martin F. Fromm,et al.  Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters , 2008, Diabetes.

[55]  K. Maeda,et al.  DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1 , 2006, Drug Metabolism and Disposition.

[56]  G R Wilkinson,et al.  OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[57]  Balram Chowbay,et al.  Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients , 2006, Pharmacogenetics and genomics.

[58]  J. González‐Gallego,et al.  Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. , 2003, The Biochemical journal.

[59]  S. Vavricka,et al.  Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver , 2002, Hepatology.

[60]  Kazuya Maeda,et al.  PREDOMINANT CONTRIBUTION OF OATP1B3 TO THE HEPATIC UPTAKE OF TELMISARTAN, AN ANGIOTENSIN II RECEPTOR ANTAGONIST, IN HUMANS , 2006, Drug Metabolism and Disposition.

[61]  Yaming Su,et al.  Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. , 2004, Molecular pharmaceutics.

[62]  C. Funk,et al.  Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3 , 2007, Drug Metabolism and Disposition.

[63]  J. Nezu,et al.  Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[64]  D. Keppler,et al.  Localization and Genomic Organization of a New Hepatocellular Organic Anion Transporting Polypeptide* , 2000, The Journal of Biological Chemistry.

[65]  R. Kim,et al.  The Human Organic Anion Transport Protein SLC21A6 Is Not Sufficient for Bilirubin Transport* , 2003, Journal of Biological Chemistry.

[66]  Kazuya Maeda,et al.  Investigation of the Inhibitory Effects of Various Drugs on the Hepatic Uptake of Fexofenadine in Humans , 2008, Drug Metabolism and Disposition.

[67]  J. Nezu,et al.  Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. , 2000, Biochemical and biophysical research communications.

[68]  Michael Böhm,et al.  Organic anion transporting polypeptide 2B1 is a high‐affinity transporter for atorvastatin and is expressed in the human heart , 2006, Clinical pharmacology and therapeutics.

[69]  A. Aguzzi,et al.  Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. , 2000, The Journal of pharmacology and experimental therapeutics.

[70]  P. Neuvonen,et al.  Plasma concentrations of active simvastatin acid are increased by gemfibrozil , 2000, Clinical pharmacology and therapeutics.

[71]  I. Tamai,et al.  Identification of influx transporter for the quinolone antibacterial agent levofloxacin. , 2007, Molecular pharmaceutics.

[72]  Wei Zhang,et al.  Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. , 2006, British journal of clinical pharmacology.

[73]  P. Meier,et al.  Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. , 2001, Gastroenterology.

[74]  P. Meier,et al.  The superfamily of organic anion transporting polypeptides. , 2003, Biochimica et biophysica acta.

[75]  S. Higuchi,et al.  Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy , 2009, Cancer Chemotherapy and Pharmacology.

[76]  Peter J. Meier,et al.  Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties , 2004, Pflügers Archiv.

[77]  Steffen Bauer,et al.  Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics , 2004, Clinical pharmacology and therapeutics.

[78]  J. Sahi,et al.  Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034. , 2006, Chemico-biological interactions.

[79]  N. Ichimaru,et al.  Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. , 2001, Atherosclerosis.

[80]  A. Wenzel,et al.  Localization of organic anion transporting polypeptides in the rat and human ciliary body epithelium. , 2005, Experimental eye research.

[81]  A. Gavazzi,et al.  Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. , 1993, Transplantation proceedings.

[82]  A. Åsberg,et al.  Substantially elevated levels of atorvastatin and metabolites in cyclosporine‐treated renal transplant recipients , 2004, Clinical pharmacology and therapeutics.

[83]  G. Groothuis,et al.  Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. , 1999, The Journal of pharmacology and experimental therapeutics.

[84]  J. D. Karkas,et al.  Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. , 1993, Nephron.

[85]  Tsuyoshi Mikkaichi,et al.  The organic anion transporter (OATP) family. , 2004, Drug metabolism and pharmacokinetics.

[86]  Mikko Niemi,et al.  Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics , 2005, Clinical pharmacology and therapeutics.

[87]  Kaoru Kobayashi,et al.  Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells , 2005, Pharmacogenetics and genomics.

[88]  J. Brockmöller,et al.  The Polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 Allele *3 Independently Affect Torsemide Pharmacokinetics and Pharmacodynamics , 2008, Clinical pharmacology and therapeutics.

[89]  S. Ekins,et al.  Comparative Pharmacophore Modeling of Organic Anion Transporting Polypeptides: A Meta-Analysis of Rat Oatp1a1 and Human OATP1B1 , 2005, Journal of Pharmacology and Experimental Therapeutics.

[90]  Yuichi Sugiyama,et al.  Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A , 2003, Journal of Pharmacology and Experimental Therapeutics.

[91]  Conrad C. Huang,et al.  Interaction of Methotrexate with Organic-Anion Transporting Polypeptide 1A2 and Its Genetic Variants , 2006, Journal of Pharmacology and Experimental Therapeutics.

[92]  A. Sekine,et al.  Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins , 2001, Journal of Human Genetics.

[93]  Kazuya Maeda,et al.  Multiple Human Isoforms of Drug Transporters Contribute to the Hepatic and Renal Transport of Olmesartan, a Selective Antagonist of the Angiotensin II AT1-Receptor , 2007, Drug Metabolism and Disposition.

[94]  L. Benet,et al.  Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[95]  D. Keppler,et al.  A Naturally Occurring Mutation in the SLC21A6Gene Causing Impaired Membrane Localization of the Hepatocyte Uptake Transporter* , 2002, The Journal of Biological Chemistry.

[96]  J. Nezu,et al.  Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human , 2004, Journal of Pharmacology and Experimental Therapeutics.

[97]  L Landmann,et al.  Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. , 2001, Gastroenterology.

[98]  Y. Sugiyama,et al.  Vectorial Transport of Enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in Rat and Human Livers , 2006, Journal of Pharmacology and Experimental Therapeutics.

[99]  Jae-Gook Shin,et al.  The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15 , 2008, Pharmacogenetics and genomics.

[100]  Mikko Niemi,et al.  Role of OATP transporters in the disposition of drugs. , 2007, Pharmacogenomics.

[101]  A. Sparreboom,et al.  Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination , 2005, Expert opinion on drug metabolism & toxicology.

[102]  B. Stieger,et al.  Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil , 2007, Drug Metabolism and Disposition.

[103]  R. Fox,et al.  Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone. , 2003, Rheumatology.

[104]  P. Neuvonen,et al.  Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. , 2007, British journal of clinical pharmacology.

[105]  P. Neuvonen,et al.  Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. , 2005, Basic & clinical pharmacology & toxicology.

[106]  T. Abe,et al.  Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. , 2008, Cancer letters.

[107]  S. D. de Morais,et al.  Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. , 2004, Chemico-biological interactions.

[108]  Y. Sugiyama,et al.  Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil , 2004, Journal of Pharmacology and Experimental Therapeutics.

[109]  S. Baker,et al.  Interaction of Imatinib with Human Organic Ion Carriers , 2008, Clinical Cancer Research.

[110]  G. Folkers,et al.  Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. , 2002, Molecular endocrinology.

[111]  Gerd Folkers,et al.  Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. , 2007, American journal of physiology. Cell physiology.

[112]  Shigeki Sugiura,et al.  ROLE OF ORGANIC ANION TRANSPORTER OATP1B1 (OATP-C) IN HEPATIC UPTAKE OF IRINOTECAN AND ITS ACTIVE METABOLITE, 7-ETHYL-10-HYDROXYCAMPTOTHECIN: IN VITRO EVIDENCE AND EFFECT OF SINGLE NUCLEOTIDE POLYMORPHISMS , 2005, Drug Metabolism and Disposition.

[113]  D. Keppler,et al.  Human Hepatobiliary Transport of Organic Anions Analyzed by Quadruple-Transfected Cells , 2005, Molecular Pharmacology.

[114]  P. Neuvonen,et al.  High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). , 2004, Pharmacogenetics.

[115]  Y. Sawada,et al.  CITRUS JUICES INHIBIT THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-B , 2005, Drug Metabolism and Disposition.

[116]  A. Sparreboom,et al.  Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel , 2005, Cancer biology & therapy.

[117]  K. Maeda,et al.  Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril , 2006, Clinical pharmacology and therapeutics.

[118]  Maria J Perez,et al.  OATP8/1B3-mediated Cotransport of Bile Acids and Glutathione , 2006, Journal of Biological Chemistry.

[119]  P. Neuvonen,et al.  Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance , 2003, Clinical pharmacology and therapeutics.

[120]  R. Kim,et al.  Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics , 2006, Clinical pharmacology and therapeutics.

[121]  H. Fujino,et al.  Transporter‐mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG‐CoA reductase , 2005, The Journal of pharmacy and pharmacology.

[122]  P. Neuvonen,et al.  Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate , 2001, Clinical pharmacology and therapeutics.

[123]  Paul D. Martin,et al.  Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine , 2004, Clinical pharmacology and therapeutics.

[124]  Y. Sugiyama,et al.  Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

[125]  Lisa Anne Hendricks,et al.  Pharmacokinetics of the combination of fluvastatin and gemfibrozil. , 1995, The American journal of cardiology.

[126]  M. Niemi,et al.  Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism , 2008, Clinical pharmacology and therapeutics.

[127]  P. Meier,et al.  Multispecific amphipathic substrate transport by an organic anion transporter of human liver. , 1996, Journal of hepatology.

[128]  R. Kim,et al.  Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans , 2007, Clinical pharmacology and therapeutics.

[129]  J. Nezu,et al.  Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. , 2002, The Journal of pharmacology and experimental therapeutics.

[130]  T. Abe,et al.  Printed in U.S.A. Copyright © 2001 by The Endocrine Society Identification of Thyroid Hormone Transporters in Humans: Different Molecules Are Involved in a , 2000 .

[131]  H. McLeod,et al.  Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics , 2007, Clinical pharmacology and therapeutics.

[132]  A. Hartmann,et al.  Bilateral Pharmacokinetic Interaction Between Cyclosporine A and Atorvastatin in Renal Transplant Recipients , 2001, American Journal of Transplantation.

[133]  Olivier Fardel,et al.  Differential Regulation of Sinusoidal and Canalicular Hepatic Drug Transporter Expression by Xenobiotics Activating Drug-Sensing Receptors in Primary Human Hepatocytes , 2006, Drug Metabolism and Disposition.

[134]  P. Neuvonen,et al.  Gemfibrozil greatly increases plasma concentrations of cerivastatin , 2002, Clinical pharmacology and therapeutics.

[135]  U. Hofmann,et al.  Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid‐lowering efficacy of multiple‐dose pravastatin , 2006, Clinical pharmacology and therapeutics.

[136]  T. Abe,et al.  OATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKER , 2006, Drug Metabolism and Disposition.

[137]  Kazuya Maeda,et al.  CONTRIBUTION OF OATP (ORGANIC ANION-TRANSPORTING POLYPEPTIDE) FAMILY TRANSPORTERS TO THE HEPATIC UPTAKE OF FEXOFENADINE IN HUMANS , 2005, Drug Metabolism and Disposition.

[138]  P. Neuvonen,et al.  Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide , 2003, Diabetologia.

[139]  A. Sparreboom,et al.  Influence of Solute Carriers on the Pharmacokinetics of CYP3A4 Probes , 2008, Clinical pharmacology and therapeutics.

[140]  H. Teng,et al.  Risk Factors for Severe Hyperbilirubinemia in Neonates , 2004, Pediatric Research.

[141]  W. Jaross,et al.  Pharmacokinetics and Pharmacodynamics of Fluvastatin in Heart Transplant Recipients Taking Cyclosporine A , 2001, Journal of cardiovascular pharmacology and therapeutics.

[142]  H. Glaeser,et al.  The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members. , 2008, Expert opinion on drug metabolism & toxicology.

[143]  M. Fromm,et al.  Pharmacogenomics of human OATP transporters , 2006, Naunyn-Schmiedeberg's Archives of Pharmacology.

[144]  P. Neuvonen,et al.  SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin , 2006, Clinical pharmacology and therapeutics.

[145]  R. Kim,et al.  Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants , 2007, Pharmacogenetics and genomics.

[146]  Nashville Tennessee,et al.  Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2) , 2005, Journal of Biological Chemistry.

[147]  L Fritsche,et al.  Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine‐treated kidney transplant recipients , 1999, Clinical pharmacology and therapeutics.

[148]  P. Neuvonen,et al.  The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. , 2008, British journal of clinical pharmacology.

[149]  C. V. Jongeneel,et al.  Identification of the gonad-specific anion transporter SLCO6A1 as a cancer/testis (CT) antigen expressed in human lung cancer. , 2004, Cancer immunity.

[150]  Xin Xu,et al.  HEPATIC UPTAKE OF THE NOVEL ANTIFUNGAL AGENT CASPOFUNGIN , 2005, Drug Metabolism and Disposition.

[151]  K. Brøsen,et al.  Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide , 2004, European Journal of Clinical Pharmacology.

[152]  A. D. Rodrigues,et al.  GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS , 2006, Drug Metabolism and Disposition.

[153]  Y Vanrenterghem,et al.  Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with Tacrolimus , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[154]  T. Abe,et al.  Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. , 2001, The Journal of pharmacology and experimental therapeutics.

[155]  S. Vavricka,et al.  Regional Distribution of Solute Carrier mRNA Expression Along the Human Intestinal Tract , 2007, Drug Metabolism and Disposition.

[156]  U. Christians,et al.  Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine‐treated kidney graft patients after multiple doses , 1997, Clinical pharmacology and therapeutics.

[157]  P. Neuvonen,et al.  Global analysis of genetic variation in SLCO1B1. , 2008, Pharmacogenomics.

[158]  Hyeong-Seok Lim,et al.  Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. , 2008, Lung cancer.

[159]  P. Neuvonen,et al.  Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide , 2008, Journal of clinical pharmacology.